Extracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY
Newborns with congenital heart disease (CHD) are at increased risk of developing postpartum and postoperative blood clots after cardiac surgery. The molecular mechanisms that are responsible for the clotting profile predisposing children to blood clots in the early stages of life are currently not well described. The goal of this proposal is to prospectively collect plasma samples from ten (10) neonates with antenatal diagnosis of severe congenital heart disease (CHD) to better understand mechanisms responsible for abnormal clotting in the perioperative period.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 1 day
Maximum Age: 7 days
Healthy Volunteers: f
View:
• All neonates with a diagnosis of severe Congenital Heart Disease undergoing surgery at Boston Children's Hospital in the first week of life
Locations
United States
Massachusetts
Boston Children's Hospital
RECRUITING
Boston
Contact Information
Primary
Rachel Bernier, MPH
rachel.bernier@childrens.harvard.edu
857-218-5348
Backup
Hanna Van Pelt, BS
hanna.vanpelt@childrens.harvard.edu
Time Frame
Start Date:2024-10-31
Estimated Completion Date:2026-12-01
Participants
Target number of participants:10
Treatments
Neonates with Congenital Heart Disease
Neonates born with severe Congenital Heart Disease undergoing corrective heart surgery within the first week of life under cardiopulmonary bypass at Boston Children's Hospital will be eligible for participation. As part of standard clinical care, neonates having cardiac surgery at Boston Children's Hospital have clinical labs drawn during and after surgery. All blood collected from neonates as part of this study will be discarded blood from those routine clinical samples. One sample will be taken before surgery and one sample will be taken after surgery.